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Human cytomegalovirus (HCMV) was first reported to be strongly associated with human malignant gliomas in 2002.
HCMV is a herpesvirus that causes congenital brain infection and multi-organ disease in immumocompromised
individuals. Malignant gliomas are the most common and aggressive adult brain tumors and glioblastoma
multiforme (GBM), the highest grade glioma, is associated with a life expectancy of less than two years. HCMV gene
products encode for multiple proteins that can promote the various signaling pathways critical to tumor growth,
including those involved in mitogenesis, mutagenesis, apoptosis, inflammation, angiogenesis, invasion and immuno-
evasion. Several groups have now demonstrated that human malignant gliomas are universally infected with HCMV
and express gene products that can promote key signaling pathways in glioma pathogenesis. In this review I discuss
specific HCMV gene products that we and others have recently found to be expressed in GBM in vivo, including the
HCMV IE1, US28, gB and IL-10 proteins. The roles these HCMV gene products play in dysregulating key pathways in
glioma biology, including the PDGFR, AKT, STAT3, and monocyte/microglia function are discussed. Finally, I review
emerging human clinical trials for GBM based on anti-HCMV strategies.
Glioblastoma Clinical
Malignant gliomas are the most common cerebral tumors,
account for about 4% of cancer deaths, and grade IV glio-
mas, glioblastoma multiforme (GBM), are the most
aggressive [1]. Despite recent advances in radiotherapy
and chemotherapy, the prognosis for GBM patients is a
median survival after diagnosis of about 14 months [1].
No significant gains in the understanding of the etiology
of GBM has occurred in the last several decades, and
except for very rare genetic cancer syndromes and expo-
sure to ionizing radiation, there is no known cause for
gliomas [2].
Glioma biology
Despite the lack of a known etiological agent for GBM,
recent findings have led to important insights into mole-
cular pathways involved in gliomagenesis. These findings
suggest that GBM cells may arise from two pathways.
One potential pathway would involve post-mitotic astro-
cytic cells that have de-differentiated into immature
tumor cells. Alternatively, the tumor arises by the
immortalization and transformation of resident neuo-
glial precursor stem cells (NPCs) in the adult brain [3,4].
One of the most important recent observations regard-
ing the biology of GBM is that these tumors, like other
hematological and solid tumors, are comprised of a subpo-
pulation of tumor initiating cells with stem-like character-
istics, often termed “cancer stem cells” or glioma stem
cells (GSC) [5,6]. These cells often express the CD133 sur-
face glycoprotein, and are therefore defined as CD133+
cells [5,7]. GSCs likely represent the most important tar-
gets of the GBM cells in terms of therapy, since these cells
are more resistant to radiation and chemotherapy, and
also may be immunosuppressive [7-9]. These cells also
appear to play a critical role in re-initiating tumor growth
after standard therapies, and thus may play a central role
in tumor recurrence. Indeed, in vitro, these cells can act as
tumor-founding cells down to the single cell level, and the
tumors they produce in animal models closely resemble
the main histological properties of GBM [10].
Key signaling pathways involved in promoting GBM
pathogenesis in the susceptible cell types. ie., NPCs, are
those that lead to sustained activation of receptor tyro-
sine kinase (RTK) signaling pathways such as EGFR and
PDGFRa, and downstream PI3-K/AKT pathways, as well
as those that inactivate important tumor suppressor
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[3,11,12]. For example, sustained activation of PDGFRa
in susceptible neuroglial precursor stem cells within the
adult brain may promote the earliest steps of gliomagen-
esis. In adult mice, infusion of PDGF into the environ-
ment of NPCs that express PDGFRa can lead to early
hyperpastic astrocytic lesions that have many characteris-
tics of early stage gliomas [13].
An increased understanding of the role of stem cell
maintenance factors in sustaining GSCs has led to the
increased appreciation that key regulators of self-renewal,
such as Sox2 and Bmi-1 may be important for sustaining
viability of the GSC population [14-16]. Another impor-
tant transcriptional activator that controls GSC mainte-
nance and is also important in myriad other signaling
pathways in GBM cells that control angiogenesis, tumor
cell invasion, apoptosis and immunosuppression, is signal
transducer and activator of transcription 3 (STAT3)
[8,9,17-19]. Indeed, STAT3 transcriptional activation,
along with activation of CEBPb, is thought to play a fun-
damental role in the transition of GBM cells into those
types of GBMs with the most aggressive, mesenchymal,
features and poor survival [20].
HCMV
Ten years ago, our group became interested in the possi-
bility that a viral infection might be involved in the
pathogenesis of GBM since our research indicated that
these tumors had characteristics of a chronic inflamma-
tory state [21,22]. Human cytomegalovirus (HCMV) was
a potential candidate since HCMV is the most common
infection of human fetal brain, and HCMV was known to
be able to persistently infect glioma cells and become
reactivated in a chronic inflammatory state and in the
setting of immunosuppression [23-26]. In 2002, we
reported that HCMV proteins and nucleic acids could be
detected in virtually all GBMs evaluated, but not in nor-
mal brain or other benign brain tumors [27]. Although
these findings were not reproduced initially [28,29], sev-
eral groups were subsequently able to confirm these find-
ings using highly sensitive techniques we developed that
detect low levels of viral expression [30-34].
History of HCMV in cancer
Although in 2002 HCMV was not considered to be an
oncogenic virus, previous work by multiple investigators
had suggested that HCMV could promote oncogenesis.
Initially, Rapp and colleagues in the 1970s had demon-
strated that urogenital isolates of HCMV could transform
cells [35]. Subsequently in the 1980’s and 1990’s, other
groups determined that HCMV possessed potentially
oncogenic gene products [36,37]. A group led by Cinatl
et al demonstrated multiple oncomodulatory aspects of
HCMV over the ensuing years (reviewed in [38,39]). The
current thinking among experts in this area is that
HCMV does not possess acute transforming activity;
rather HCMV gene products may be “oncomodulatory”.
In such a situation, expression of HCMV gene products
in an established tumor may accelerate progression of
the tumor by influencing multiple key pathways such as
angiogenesis, invasion, mitogenesis, immunomodulation,
etc.
Mechanisms of glioma promotion
Upon discovering that HCMV infection was prevalent in
malignant gliomas, we attempted to determine whether
viral infection might promote glioma pathogenesis. Since
the HCMV IE1 gene product was readily detected in
tumors, and since this viral gene was previously known to
be mutagenic and a potent viral transcriptional activator
[38,40], we sought to determine the impact of IE1 expres-
sion in GBM cells. We found that IE1 expression caused
increased proliferation of GBM cell lines and primary
explant cells [41]. This phenomenon was associated with
IE1-mediated inactivation of the p53 and Rb tumor sup-
pressor proteins, and activation of the PI3-K/AKT signal-
ing pathway [41]. IE1 promoted cell cycle entry and DNA
synthesis of human glioma cells on both stable expression
in tumor-derived cell lines as well as transient expression
in primary glioblastoma cells. Our findings were consistent
with those of others who have demonstrated that the
HCMV IE1 gene product can block p53 transcriptional
activity and induce a dominant negative p53 family mem-
ber protein [42,43].
These findings were also consistent with those from
another group demonstrating that IE1 expression in a
GBM cell line could lead to decreased expression of
thrombospondin-1 (TSP-1), GFAP, and p53 [44]. Since
TSP-1 inhibits angiogenesis and GFAP is associated with
a more differentiated astrocytic phenotype [45], these
results suggested that, in addition to promoting glioma
cell mitogenesis, expression of IE1 in glioma cells may
also promote GBM angiogenesis, and a de-differentiated
state, along with loss of tumor suppressor activity. Inter-
estingly, we found that expression of HCMV IE1 in nor-
mal human astrocytes or normal fibroblasts resulted in
either no change in proliferation or a decreased prolifera-
tion, respectively. This result suggests that expression of
HCMV IE1 may have a paradoxical effect on cells based
on their neoplastic or differentiation state - promoting
proliferation in neoplastic cells while exerting the oppo-
site effect on wild-type cells.
In the last few years, other groups have made further
advances with respect to elucidating how HCMV gene
products may impact gliomagenesis. In 2009, Straat et
al. showed that IE1 expression in GBM cells was asso-
ciated with induction of telomerase activity [32]. HCMV
IE1 protein stimulated hTERT promoter activity, and in
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were co-localized in malignant cells and their levels par-
alleled each other. Since telomerase activation can lead
to cellular immortalization and telomerase activation
has been observed in 90% of cancers [46], these findings
suggest that HCMV IE1 mediated activation of telomer-
ase may contribute to oncogenesis in glioma.
Consistent with these observations, Scheurer et al. found
that the level of IE1 expression in malignant gliomas was
positively correlated to the grade of tumor, with GBM
having the highest levels of expression [31]. In addition,
the level of IE1 expression in GBM has been found to
inversely correlate with patient survival [47].
While IE1 expression in a tumor cell may promote
important oncogenic signaling pathways, we also became
interested in the possibility that HCMV might promote
sustained RTK activation, which is a hallmark of GBM
p a t h o g e n e s i s .W ea n do t h e r sh a do b s e r v e dt h a tH C M V
attachment caused activation of RTK signaling, and that a
RTK was potentially causing HCMV-mediated PI3-K/
AKT signaling [48]. In exploring this phenomenon, we
discovered that activation of the PDGFRa receptor was
essential for HCMV infection [49]. Furthermore, we
observed that the HCMV gB envelope glycoprotein binds
specifically to PDGFRa upon viral attachment and func-
tions like the authentic ligand PDGF in terms of activating
downstream RTK signaling of the PI3-K/AKT signaling
pathway [49]. Blockade of PDGFRa with a blocking anti-
body or with the PDGFRa small molecule inhibitor Glee-
vec
® completely inhibited HCMV entry into the cell, viral
expression and replication [49]. These findings immedi-
ately raised the possibility that expression of the HCMV
gB glycoprotein on the cell surface of glial precursor stem
cells or GBM cells that overexpress PDGFRa may facili-
tate autocrine or paracrine activation of the PDGFRa sig-
naling pathway, which plays a major role in glioma
pathogenesis. Ongoing studies in our laboratory are inves-
tigating this hypothesis.
In addition to sustained mitogenesis and inhibition of
tumor suppressor function, another key event in oncogen-
esis is blockade of cellular differentiation. If HCMV infec-
tion of NPCs could promote the PDGFRa - PI3K/AKT
signaling pathway while simultaneously blocking their
ability to differentiate, this would greatly increase the like-
lihood of neoplastic transformation. This hypothetical sce-
nario could occur in HCMV infected NPCs, since these
cells are fully permissive to HCMV infection [50] and
since HCMV gene products block the ability of NPCs to
differentiate into neurons and astrocytes [51-53].
HCMV and the US28 - STAT3 Signaling Pathway
Since the STAT3 signaling pathway may play a major role
as a master regulator of glioma pathogenesis, HCMV gene
products that promote STAT3 transcriptional activation
could influence glioma biology. One such HCMV gene
product is the US28 chemokine receptor, which is bona
fide viral oncoprotein [54]. US28 binds a broad spectrum
of chemokines, including SDF-1, CCL2/MCP-1, CCL5/
RANTES, and CX3CL1/fractalkine, and, unlike its human
cellular homolog CCR1, US28 exhibits constitutive activity
[55]. Ectopic expression of US28 induces a pro-angiogenic,
transformed glioma phenotype in vivo,b yu p r e g u l a t i n g
VEGF [54]. The induction of VEGF expression as a result
of HCMV infection in U373 GBM cells was due to the
constitutive activation of US28, since a US28-deficient
mutant HCMV did not induce VEGF [54]. Thus, the
angiogenic (i.e., aggressive) phenotype in some GBMs that
express US28 might be due to the oncogenic properties of
US28 acting in concert with other viral proteins, such as
the IE1 and IE2 gene products, to facilitate tumor initia-
tion and progression after infection. Consistent with these
data, our preliminary microarray and TaqMan analyses
indicate that both IE1 and US28 are highly expressed in
patient-derived GBM biopsy specimens. In addition to its
ability to induce oncogenic transformation and promote
angiogenesis, US28 promotes cell migration toward che-
mokines RANTES and MCP-1,[56] which are abundantly
expressed in malignant gliomas [57].
Recently, Slinger et al. showed that increased concentra-
tions of VEGF and IL-6 are secreted in supernatants of
U S 2 8 - e x p r e s s i n gc e l l sa n dt h a tt h i sr e s u l t e di nd o w n -
stream activation of STAT3 [58]. They determined that
STAT3 is essential for the US28-mediated proliferative
phenotype described above. In GBM specimens from
patients, they found that US28 co-localized with pSTAT3
in the vascular niche of the tumor and that US28 induces
proliferation in HCMV-infected tumors by establishing a
positive feedback loop through activation of the IL-6-
STAT3 signaling axis [58]. These data strongly implicate
the HCMV US28 gene product as a major driver of
STAT3 signaling in GBM, a role that would implicate
US28 in GBM angiogenesis, invasion, and immune
evasion.
In addition, to explore the potential role of HCMV
US28 in colon cancer, Bongers et al. recently described a
transgenic mouse that expresses US28 in intestinal
epithelial stem cells [59]. Strikingly, these mice developed
colon adenomas and adenocarcinomas by 40 weeks of
age, a phenomenon that was enhanced by the presence of
US28 stimulatory cytokine CCL2. They noted that the
Wnt signaling pathway was activated in the US28+
tumor cells as demonstrated by US28-mediated phos-
phorylation (inactivation) of GSK3-b, and subsequent
dephosphorylation (activation) of b-catenin, and induc-
tion of downstream Wnt target genes survivin, cyclin-D1,
and c-myc [59]. In summary, both of these recent reports
indicate that HCMV US28 can drive oncogenic signaling
through two key pathways that are involved in cancer
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sion–STAT3 and GSK3-b/b-catenin.
Immune Evasion
A critical component in inflammation-associated malig-
nancies like gliomas is the loss of normal antitumor
immune function in the tumor microenvironment. In
addition to the tumor-promoting effects of HCMV infec-
tion of monocytes/macrophages, expression of HCMV
gene products by GBM cells could dramatically alter the
host’s immune response to tumor. A variety of tumor-
derived factors contribute to the emergence of complex
local and regional immunosuppressive networks, including
VEGF, IL-10, TGF-b, and PGE-2 [60,61]. Cytotoxic T lym-
phocyte (CTL; CD8+) and NK cell responses are critical
effectors of normal host antitumor immunosurveillance.
Through millions of years of co-evolution with the host,
HCMV has evolved multiple strategies to allow persistent
viral infection through a complex array of immune evasion
strategies [62-66]. Several HCMV gene products are
expressed as immediate early and early viral genes to
block the host-cell MHC class I antigen expression, which
is required for CD8+ cytotoxic tumor killing. The UL83
gene product pp65, which our laboratory and others have
consistently detected in GBM cells, blocks antigen presen-
tation of IE1, one of the earliest immunodominant HCMV
epitopes, from CD8+ T cells.
Through a complex interaction with tumor cells and
tumor associated microglia/macrophages (TAMs), HCMV
infection is also likely to impair function of tumor antigen
presentation by dendritic cells (DCs) in the tumor micro-
environment. IL-10 suppresses the maturation and cyto-
kine production of DCs, key regulators of adaptive
immunity, and prevents the activation and polarization of
naive T cells toward protective IFN-g-producing effectors.
Treatment of immature DCs with supernatant from
HCMV-infected cultures has been found to inhibit both
the lipopolysaccharide-induced DC maturation and pro-
inflammatory cytokine production [67]. Not surprisingly,
use of IL-10 is a common mechanism for intracellular
pathogens to suppress or delay the immune response and
establish productive infection in the host [68].
To maximize this strategy, HCMV encodes an UL111A
gene product that has 27% identity with human IL-10
(cmvIL-10) and that has potent immunosuppressive prop-
erties. cmvIL-10 inhibits mononuclear cell proliferation,
suppresses inflammatory cytokine production, and down-
regulates MHC expression [69]. cmvIL-10 alters the ear-
liest host responses to viral antigens by dampening the
magnitude and specificity of innate effector cells [70]. In
addition, there is a commensurate reduction in the quality
and quantity of early and long-term, HCMV-specific adap-
tive immune responses [70]. Further studies show that
cmvIL-10 inhibits DC maturation and migration [71],
effects that are likely to significantly hamper the cell-
mediated immune response to HCMV infection. Since
cmvIL-10 is likely expressed during early stages of HCMV
infection of glioma cells, this would potentially provide
these HCMV-positive tumor cells an unheralded survival
advantage against host innate and adaptive immune effec-
tor cells.
Recently, Dzurisinsky et al., used flow cytometry to ana-
lyze GBMs for evidence of HC M Va n t i g e n s[ 7 2 ] .T h e y
found that GSCs are preferentially infected in vivo by
HCMV. They also evaluated tumors for evidence of
cmvIL-10 production by ELISA and found that HCMV
showed a tropism for GSCs and macrophages/microglia
within GBMs. Furthermore, these tumor GSCs produced
cmvIL-10, which induced human monocytes to assume an
M2 immunosuppressive phenotype (as manifested by
downmodulation of the major histocompatibility complex
and costimulatory molecules) while upregulating immu-
noinhibitory B7-H1. The cmvIL-10-treated monocytes
produced angiogenic VEGF, immunosuppressive TGF-
beta, and enhanced migration of GSCs. Thus, their find-
ings indicate that HCMV triggers a feedforward mechan-
ism of gliomagenesis in vivo by inducing tumor-supportive
monocytes.
Animal model
A recently described model of murine CMV (MCMV)
infection in mice predisposed to spontaneously arising
GBMs (Mut3 mice) indicates that CMV infection can pro-
mote gliomagenesis and GBM pathogenesis. To test this
hypothesis, Price et al. infected Mut3 (GFAP-cre; Nf1loxP/
+; Trp53-/+) mice with MCMV [73]. Mut3 mice develop
normally, but eventually succumb from malignant astrocy-
tomas, including GBM, at adult age with almost complete
penetrance. MCMV infection significantly shortened sur-
vival of Mut3 mice with increased incidence of GBM com-
pared to anaplastic astrocytomas (WHO grade III). Before
tumor formation, there was a significant increase in the
Gfap- or nestin-positive NPC population by MCMV infec-
tion. Mice infected with MCMV contained an abnormal
area of increased cellularity in the subventricular zone
near the midline bilaterally. The cells had spindle-shaped
nuclei and condensed chromatin. Interestingly, this is the
area where NPCs reside. However, there were no notice-
able changes in S100b-positive pan glia or NeuN-positive
neurons. These data suggest that CMV infection acceler-
ates GBM progression by affecting the NPC population.
Therapeutic implications
The observations described above led a research team at
the Karolinska Institute in Stockholm to initiate a clinical
trial of the antiviral drug Valcyte in glioblastoma patients.
This Phase II prospective randomized clinical trial began
in 2006 via an investigational grant from Roche to
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http://clinicaltrials.gov/ct2/show/study/NCT00400322.
Using a randomized, double blind design to test the
safety and efficacy of the drug, 42 patients were enrolled.
Patients received 900 mg Valcyte twice daily for three
weeks followed by a maintenance dose (900 mg once
daily) for an additional 21 weeks. MRI scans were per-
formed pre and post operatively, and at 12 and 24 weeks.
No serious adverse events were clearly linked to Valcyte
treatment. Subject followup is still ongoing.
Work by Duke University scientists has resulted in an
immunotherapy approach to attack CMV infection in
GBM. Clinical results to date also support the concept
that an anti-CMV approach to this disease may have
clinical benefit. A Phase I/II immunotherapy clinical
trial of autologous CMV pp65 RNA loaded dendritic
cells (DCs) was initiated in 2006 (ATTAC Protocol-
FDA-IND-BB-12839; Duke IRB Protocol 8108; PI:
Duane A. Mitchell). This trial enrolled 13 patients with
newly diagnosed GBM who underwent gross total resec-
tion (> 95%) followed by standard external beam radia-
tion (60 Gy) and concurrent temozolomide (TMZ) (75
mg/m
2/d) for six weeks followed by monthly 5 day
TMZ (150-200 mg/m
2/d) for six cycles. Leukapheresis
harvested post surgical resection and prior to initiation
of TMZ was used to generate DCs and pp65 RNA elec-
troporated autologous DCs (2 × 10
7 DCs i.d.) were
administered every two weeks for the first three doses
after first TMZ cycle and monthly thereafter on day 21
of each cycle. Patients were monitored by MRI (every
two months) for tumor progression and blood was col-
lected monthly for immunologic monitoring. Initial
results are highly encouraging. Patients exhibited a med-
ian progression-free survival (PFS) of 15.4 months and
an overall survival OS of 20.6 months. Both outcomes
are highly significant compared to matched historical
controls (p = 0.004). Duke investigators have plans to
pursue this immunotherapy strategy with a second gen-
eration peptide based vaccine to CMV to be delivered
alongside with lymphopenia inducing doses of TMZ to
GBM patients. This “PEP-CMV” Phase I/II clinical trial
will be pursued at multiple institutions through the NCI
Brain Tumor SPORE mechanism.
Summary
Growing evidence indicates that HCMV infection occurs
in malignant gliomas in vivo and that HCMV gene pro-
ducts can promote important oncogenic pathways and
phenotypes that likely contribute to glioma pathogen-
esis. The implications of this growing field are that
HCMV infection is not merely an epiphenomenon in
the glioma neoplastic process; rather viral gene expres-
sion can promote tumor aggressiveness and possibly
play a causal role in gliomagenesis. Observations to date
implicate the HCMV IE1, gB, IL-10 and US28 gene pro-
ducts as tumor promoters in gliomagenesis (Figure 1).
Figure 1 HCMV promotes GBM pathogenesis. HCMV utilizes multiple mechanisms to promote oncogenesis and subvert the host anti-tumor
immune function. HCMV envelope glycoprotein B (gB) attaches to and activates PDGFRa signaling. HCMV gene products IE1 and US28 drive
multiple cellular pathways important in gliomagenesis such as PI3-K/AKT, pSTAT3, and GSK3-b. The STAT3 pathway is a master regulator of
glioma proliferation, apoptosis, angiogenesis, invasion and tumor stem cell maintenance. Other HCMV gene products, and the cmvIL-10 cytokine,
lead to further expression of host factors like IL-10 and TGFb which subvert host anti-tumor immune responses.
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glioma grade and patient survival. An animal model of
CMV infection in the setting of gliomagenesis suggests
that CMV can promote the progression of developing
gliomas to becoming GBMs, possibly by enhanced mito-
genesis within the vulnerable NPC population. Prelimin-
ary clinical trials in humans with GBM suggest that
both direct antiviral therapeutic interventions and vac-
cine based therapies may impact tumor progression and
increase patient survival. This cumulative body of data
supports further investigations into the role of HCMV
in malignant glioma pathogenesis and therapy.
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